Zofran: Effective Relief from Nausea and Vomiting
Zofran
| Product dosage: 4mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 90 | 0.57 $ | 51.48 $ (0%) | 🛒 Add to cart |
| 120 | 0.52 $ | 68.64 $ 62.01 $ (10%) | 🛒 Add to cart |
| 180 | 0.45 $ | 102.96 $ 81.90 $ (20%) | 🛒 Add to cart |
| 270 | 0.41 $ | 154.44 $ 111.15 $ (28%) | 🛒 Add to cart |
| 360 | 0.39 $
Best per pill | 205.92 $ 140.40 $ (32%) | 🛒 Add to cart |
Zofran (ondansetron) is a leading prescription medication specifically formulated to prevent and treat nausea and vomiting. It is a potent 5-HT3 receptor antagonist, a class of drug renowned for its efficacy in managing emesis triggered by chemotherapy, radiotherapy, and post-operative recovery. By selectively blocking serotonin receptors in the brain and gut, Zofran interrupts the signals that trigger the vomiting reflex, offering rapid and reliable control. It is a cornerstone therapy in both hospital and outpatient settings, trusted by oncologists, anesthesiologists, and general practitioners for its consistent performance and favorable safety profile.
Features
- Active Ingredient: Ondansetron hydrochloride.
- Available Formulations: Oral tablets (4mg, 8mg), orally disintegrating tablets (4mg, 8mg), oral solution (4mg/5mL), and injectable solution for intravenous or intramuscular use (2mg/mL).
- Mechanism of Action: Selective serotonin 5-HT3 receptor antagonist.
- Onset of Action: Oral forms typically begin working within 1-2 hours; intravenous administration can provide effects within minutes.
- Duration of Effect: Provides control for up to 8-12 hours following a single dose, depending on indication and formulation.
- Prescription Status: Available by prescription only.
Benefits
- Superior Emesis Control: Effectively prevents and treats nausea and vomiting, allowing patients to maintain hydration, nutrition, and comfort.
- Enables Critical Treatment Compliance: By managing chemotherapy-induced nausea and vomiting (CINV), it allows patients to complete full courses of potentially curative cancer treatment.
- Facilitates smoother Post-operative Recovery: Reduces post-operative nausea and vomiting (PONV), leading to faster ambulation, shorter recovery room stays, and improved patient satisfaction.
- Multiple Administration Options: Availability of tablets, orally disintegrating forms, and injectable solutions ensures therapy can be tailored to patients who have difficulty swallowing or are actively vomiting.
- Generally Well-Tolerated: Has a well-established safety profile with a low incidence of severe side effects, such as extrapyramidal symptoms, common with older antiemetic agents.
Common use
Zofran is indicated for the prevention of nausea and vomiting associated with:
- Highly and Moderately Emetogenic Cancer Chemotherapy: A primary choice for managing acute-phase CINV.
- Radiotherapy: For patients receiving total body irradiation or fractionated abdominal radiation.
- Post-operative Nausea and Vomiting (PONV): Administered prophylactically before surgery or for treatment after surgery. It is also used off-label for severe cases of nausea and vomiting related to gastroenteritis, migraine, and vertigo, though this is at the discretion of a prescribing physician.
Dosage and direction
Dosage is highly indication-specific and must be determined by a healthcare professional.
- Chemotherapy-Induced Nausea and Vomiting (Adults): A common regimen is 8mg orally or IV 30 minutes before chemotherapy, followed by 8mg orally every 12 hours for 1-2 days after.
- Radiation-Induced Nausea and Vomiting (Adults): 8mg orally taken 1-2 hours before radiotherapy, and every 8 hours after as needed.
- Post-operative Nausea and Vomiting (Adults): 16mg orally or 4mg IV undiluted administered over 2-5 minutes immediately before anesthesia induction or for treatment post-operation.
- Pediatric Use: Dosage is based on body surface area for chemotherapy and weight for post-operative use. The oral solution or disintegrating tablets are often preferred.
- Administration: Tablets should be swallowed whole with water. Orally disintegrating tablets are placed on the tongue and will dissolve without water. The oral solution should be measured with the provided dosing spoon or syringe. The injectable form is for clinical administration only.
Precautions
- QT Prolongation: Zofran can prolong the QT interval on an electrocardiogram. Use with caution in patients with congenital long QT syndrome, congestive heart failure, bradyarrhythmias, or those taking other drugs that prolong the QT interval. Electrolyte imbalances (e.g., hypokalemia, hypomagnesemia) should be corrected.
- Serotonin Syndrome: There is a potential risk of serotonin syndrome, particularly when used concomitantly with other serotonergic drugs (e.g., SSRIs, SNRIs, tramadol). Monitor for symptoms such as agitation, hallucinations, tachycardia, and hyperthermia.
- Masking of Ileus: In post-operative patients, Zofran can mask the symptoms of a developing bowel obstruction or ileus. Monitor abdominal status closely.
- Phenylketonuria (PKU): The orally disintegrating tablets contain aspartame, which is a source of phenylalanine (approximately 1.5 mg and 3 mg per 4 mg and 8 mg tablet, respectively).
- Hepatic Impairment: A maximum daily dose of 8mg is recommended for patients with severe hepatic impairment due to reduced clearance.
Contraindications
Zofran is contraindicated in patients with:
- Known hypersensitivity to ondansetron or any components of the formulation.
- Concomitant use of apomorphine due to the risk of profound hypotension and loss of consciousness.
Possible side effect
The most commonly reported side effects are generally mild and transient.
- Very Common (>10%): Headache, constipation.
- Common (1-10%): Dizziness, fatigue, drowsiness, diarrhea, sensation of warmth or flushing, injection site reactions.
- Uncommon (0.1-1%): Hiccups, hypotension, transient blurred vision, electrocardiographic changes (e.g., QT prolongation, bradycardia).
- Rare (<0.1%): Seizures, movement disorders, arrhythmias (including tachycardia and atrial fibrillation), hypersensitivity reactions (e.g., anaphylaxis, bronchospasm).
Drug interaction
- QT-Prolonging Agents: Concomitant use with drugs like antiarrhythmics (e.g., amiodarone, sotalol), antipsychotics (e.g., haloperidol), and certain antibiotics (e.g., erythromycin) may have additive effects on QT prolongation, increasing the risk of torsades de pointes.
- Drugs Affecting CYP Enzymes: Ondansetron is metabolized primarily by CYP enzymes (e.g., 3A4, 1A2, 2D6). Inducers (e.g., rifampin, carbamazepine) may decrease ondansetron plasma concentrations. Inhibitors (e.g., ketoconazole, ciprofloxacin) may increase them, though dosage adjustment is not routinely recommended.
- Serotonergic Drugs: As noted in Precautions, concomitant use with other serotonergic agents increases the risk of serotonin syndrome.
Missed dose
- If a dose is missed, it should be taken as soon as it is remembered.
- However, if it is almost time for the next scheduled dose, the missed dose should be skipped. The patient should not double the dose to make up for the missed one.
- The regular dosing schedule should then be resumed.
Overdose
- Symptoms: Sudden visual disturbances (severe constipation is a potential symptom with large overdoses), dizziness, syncope, and QT prolongation leading to potential cardiac events.
- Management: There is no specific antidote for ondansetron overdose. Treatment is supportive and symptomatic, including continuous ECG monitoring for a minimum of 24 hours to monitor for QT prolongation and potential arrhythmias. Ensure adequate hydration.
Storage
- Store at room temperature between 20°C to 25°C (68°F to 77°F). Excursions are permitted between 15°C and 30°C (59°F and 86°F).
- Protect from light and moisture.
- Keep the bottle tightly closed.
- Keep all medications out of the reach of children and pets.
Disclaimer
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any new treatment. Never disregard professional medical advice or delay in seeking it because of something you have read here.
Reviews
“Zofran was a game-changer during my chemotherapy. The disintegrating tablets were a lifesaver on days I couldn’t keep anything down. I experienced minimal side effects, just a slight headache, which was a small price to pay for being able to function.” – Maria K., Breast Cancer Patient.
“As an anesthesiologist, Zofran is my first-line prophylactic for PONV in high-risk patients. Its efficacy and rapid onset via IV make it an indispensable tool for ensuring patient comfort in the recovery unit. The safety profile is excellent for short-term perioperative use.” – Dr. Evan R., MD.
“After my surgery, the nausea was overwhelming. A single dose of Zofran IV made it disappear within ten minutes. It was the difference between a miserable night and being able to rest and recover properly.” – James L.